Sailaja Kamaraju
Overview
Explore the profile of Sailaja Kamaraju including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
134
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kamaraju S, Fowler A, Tarima S, Chaudhary L, Burkard M, Giever T, et al.
Clin Breast Cancer
. 2025 Jan;
PMID: 39824712
Background: The SMILE study is a multi-institutional phase II clinical trial to determine the efficacy and safety of an antiprogestin, onapristone, in combination with fulvestrant as second-line therapy for patients...
2.
Neuner J, Stolley M, Kamaraju S, Tiegs J, Sparapani R, Makris V, et al.
Breast Cancer Res Treat
. 2024 Nov;
209(3):541-552.
PMID: 39592520
Purpose: Few risk factors for early adjuvant endocrine discontinuation have been identified, but clinical trials suggest pre-AET symptom burden might be important. We sought to assess this in an academic...
3.
Fang K, Ohihoin A, Liu T, Choppavarapu L, Nosirov B, Wang Q, et al.
Genome Med
. 2024 Nov;
16(1):134.
PMID: 39558215
Background: Inter- and intra-tumor heterogeneity is considered a significant factor contributing to the development of endocrine resistance in breast cancer. Recent advances in single-cell RNA sequencing (scRNA-seq) and single-cell ATAC...
4.
Thareja S, Yang X, Upama P, Abdullah A, Torres S, Cocroft L, et al.
J Am Med Inform Assoc
. 2024 Oct;
31(12):2940-2951.
PMID: 39441983
Objective: The NIH All of Us Research Program aims to advance personalized medicine by not only linking patient records, surveys, and genomic data but also engaging with participants, particularly from...
5.
Istl A, Lawton S, Kamaraju S, Stolley M, Petroll A, Cortina C
Ann Surg Oncol
. 2024 Jun;
31(9):5560-5569.
PMID: 38861206
Background: More than 2.5 million adults in the United States identify as transgender or gender-diverse (TGD), but little data exist on cancer screening and care for this population. We examined...
6.
Kamaraju S, McKoy J, Williams G, Gilmore N, Minami C, Bylow K, et al.
Curr Oncol Rep
. 2024 May;
26(8):855-864.
PMID: 38801612
Purpose Of Review: Cancer-related inequities are prevalent in Wisconsin, with lower survival rates for breast, colorectal, and lung cancer patients from marginalized communities. This manuscript describes the ongoing efforts at...
7.
Jorns J, Sun Y, Kamaraju S, Cheng Y, Kong A, Yen T, et al.
J Pers Med
. 2024 May;
14(5).
PMID: 38793060
PD-L1 immunohistochemistry (IHC) has become an established method for predicting cancer response to targeted anti-PD1 immunotherapies, including breast cancer (BC). The alternative PD-1 ligand, PD-L2, remains understudied but may be...
8.
Lee A, Lyons A, Makris V, Kamaraju S, Stolley M, Neuner J, et al.
Support Care Cancer
. 2024 Apr;
32(4):265.
PMID: 38565669
Purpose: Oral adjuvant endocrine therapy (AET) is an effective treatment for hormone receptor positive breast cancer to decrease recurrence and mortality, but adherence is poor. This study explored post-menopausal women's...
9.
Patel M, Hinyard L, Merrill J, Smith K, Lei J, Carrizosa D, et al.
JCO Oncol Pract
. 2024 Feb;
20(5):688-698.
PMID: 38354324
Purpose: Little data exist regarding approaches to support oncology professionals who deliver cancer care for underserved populations. In response, ASCO developed the Serving the Underserved Task Force to learn from...
10.
Pierro M, Zurko J, Szabo A, Cheng Y, Kamaraju S, Burfeind J, et al.
WMJ
. 2024 Jan;
122(5):418-421.
PMID: 38180937
Introduction: In this retrospective matched case control study, we aim to identify breast cancer-related risk factors associated with developing COVID-19 and describe outcomes of patients with breast cancer diagnosed with...